In-center Nocturnal Hemodialysis: Another Option in the Management of Chronic Kidney Disease

• Published in: Clinical journal of the American Society of Nephrology Vol. 4; no. 4; pp. 778 - 783
• Main Authors: Bugeja, Ann, Dacouris, Niki, Thomas, Alison, Marticorena, Rosa, McFarlane, Philip, Donnelly, Sandra, Goldstein, Marc
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.04.2009
• Subjects: Adult; Alkaline Phosphatase - blood; Antihypertensive Agents - therapeutic use; Attitude of Health Personnel; Biomarkers - blood; Biomarkers - urine; Calcium - blood; Chronic Disease; Circadian Rhythm; Dialysis; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; Hematinics - therapeutic use; Hemodialysis Units, Hospital; Hemoglobins - metabolism; Humans; Iron - blood; Kidney Diseases - complications; Kidney Diseases - nursing; Kidney Diseases - therapy; Male; Middle Aged; Parathyroid Hormone - blood; Phosphorus - blood; Program Evaluation; Quality of Life; Renal Dialysis - adverse effects; Renal Dialysis - methods; Renal Dialysis - nursing; Retrospective Studies; Treatment Outcome
• ISSN: 1555-9041; 1555-905X
• DOI: 10.2215/CJN.05221008

Some patients are not optimally treated by conventional in-center hemodialysis (HD) and are unable to perform home HD. We examined the effect of in-center thrice-weekly nocturnal HD (INHD) on patient outcomes. Patients who were not optimally treated on conventional HD were offered INHD. Thirty-nine patients' laboratory data and medication use were analyzed for the 12 mo before and after conversion to INHD until September 1, 2007. Quality of life on conventional HD and INHD was compared. After conversion to INHD, median values for phosphorus decreased from 5.9 to 3.7 mg/dl (P < 0.01), alkaline phosphatase level increased from 84 to 161 U/L (P < 0.01), and percentage reduction in urea increased from 74 to 89% (P < 0.01). The mean number of antihypertensive drugs prescribed declined from 2.0 to 1.5 (P < 0.05) during the course of INHD, and the mean daily dosage of phosphate binders declined from 6.2 to 4.9 at study end (P < 0.05). There was a significant reduction in erythropoietin-stimulating agent use of 1992 U/wk (P < 0.01). There was no significant change in median hemoglobin, iron saturation, corrected calcium, or parathyroid hormone levels. Overall, quality of life, sleep, intradialytic cramps, appetite, and energy level all improved significantly on INHD. INHD offers an effective form of HD for long-term dialysis patients who are unable to perform home HD.